These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26914848)

  • 1. Effect of mTORC1/mTORC2 inhibition on T cell function: potential role in graft-versus-host disease control.
    Herrero-Sánchez MC; Rodríguez-Serrano C; Almeida J; San-Segundo L; Inogés S; Santos-Briz Á; García-Briñón J; SanMiguel JF; Del Cañizo C; Blanco B
    Br J Haematol; 2016 Jun; 173(5):754-68. PubMed ID: 26914848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development.
    Herrero-Sánchez MC; Rodríguez-Serrano C; Almeida J; San Segundo L; Inogés S; Santos-Briz Á; García-Briñón J; Corchete LA; San Miguel JF; Del Cañizo C; Blanco B
    J Hematol Oncol; 2016 Oct; 9(1):113. PubMed ID: 27765055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.
    Gini B; Zanca C; Guo D; Matsutani T; Masui K; Ikegami S; Yang H; Nathanson D; Villa GR; Shackelford D; Zhu S; Tanaka K; Babic I; Akhavan D; Lin K; Assuncao A; Gu Y; Bonetti B; Mortensen DS; Xu S; Raymon HK; Cavenee WK; Furnari FB; James CD; Kroemer G; Heath JR; Hege K; Chopra R; Cloughesy TF; Mischel PS
    Clin Cancer Res; 2013 Oct; 19(20):5722-32. PubMed ID: 24030701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications.
    Montero JC; Chen X; Ocaña A; Pandiella A
    Mol Cancer Ther; 2012 Jun; 11(6):1342-52. PubMed ID: 22496482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.
    Chen X; Díaz-Rodríguez E; Ocio EM; Paiva B; Mortensen DS; Lopez-Girona A; Chopra R; Miguel JS; Pandiella A
    Mol Cancer Ther; 2014 Feb; 13(2):504-16. PubMed ID: 24431075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTORC1-S6K1 inhibition or mTORC2 activation improves hippocampal synaptic plasticity and learning in Angelman syndrome mice.
    Sun J; Liu Y; Tran J; O'Neal P; Baudry M; Bi X
    Cell Mol Life Sci; 2016 Nov; 73(22):4303-4314. PubMed ID: 27173058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro.
    Li Q; Song XM; Ji YY; Jiang H; Xu LG
    Biochem Biophys Res Commun; 2013 Nov; 440(4):701-6. PubMed ID: 24103749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammalian target of rapamycin inhibitors permit regulatory T cell reconstitution and inhibit experimental chronic graft-versus-host disease.
    Sugiyama H; Maeda Y; Nishimori H; Yamasuji Y; Matsuoka K; Fujii N; Kondo E; Shinagawa K; Tanaka T; Takeuchi K; Teshima T; Tanimoto M
    Biol Blood Marrow Transplant; 2014 Feb; 20(2):183-91. PubMed ID: 24333142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual mTORC1/mTORC2 Inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis.
    Tasneen R; Mortensen DS; Converse PJ; Urbanowski ME; Upton A; Fotouhi N; Nuermberger E; Hawryluk N
    Antimicrob Agents Chemother; 2021 Jun; 65(7):e0025321. PubMed ID: 33903099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model.
    Zhang X; Wang X; Qin L; Xu T; Zhu Z; Zhong S; Zhang M; Shen Z
    Urology; 2015 Jan; 85(1):273.e1-7. PubMed ID: 25440763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin 21 blockade modulates activated T- and B-cell homeostasis via B-cell activating factor pathway-mediated inhibition in a murine model of acute graft-versus-host disease.
    Lim JY; Park MJ; Im KI; Kim N; Park HS; Lee SH; Kim EK; Nam YS; Lee ES; Cho ML; Cho SG
    Exp Hematol; 2015 Jan; 43(1):23-31.e1-2. PubMed ID: 25246268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.
    Montero JC; Esparís-Ogando A; Re-Louhau MF; Seoane S; Abad M; Calero R; Ocaña A; Pandiella A
    Oncogene; 2014 Jan; 33(2):148-56. PubMed ID: 23246963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014.
    Huo HZ; Zhou ZY; Wang B; Qin J; Liu WY; Gu Y
    Biochem Biophys Res Commun; 2014 Jan; 443(2):406-12. PubMed ID: 24309100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTORC2 Deficiency in Myeloid Dendritic Cells Enhances Their Allogeneic Th1 and Th17 Stimulatory Ability after TLR4 Ligation In Vitro and In Vivo.
    Raïch-Regué D; Rosborough BR; Watson AR; McGeachy MJ; Turnquist HR; Thomson AW
    J Immunol; 2015 May; 194(10):4767-76. PubMed ID: 25840913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
    J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T Cells Encountering Myeloid Cells Programmed for Amino Acid-dependent Immunosuppression Use Rictor/mTORC2 Protein for Proliferative Checkpoint Decisions.
    Van de Velde LA; Subramanian C; Smith AM; Barron L; Qualls JE; Neale G; Alfonso-Pecchio A; Jackowski S; Rock CO; Wynn TA; Murray PJ
    J Biol Chem; 2017 Jan; 292(1):15-30. PubMed ID: 27903651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition.
    Limon JJ; So L; Jellbauer S; Chiu H; Corado J; Sykes SM; Raffatellu M; Fruman DA
    Proc Natl Acad Sci U S A; 2014 Nov; 111(47):E5076-85. PubMed ID: 25385646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined OX40L and mTOR blockade controls effector T cell activation while preserving T
    Tkachev V; Furlan SN; Watkins B; Hunt DJ; Zheng HB; Panoskaltsis-Mortari A; Betz K; Brown M; Schell JB; Zeleski K; Yu A; Kirby I; Cooley S; Miller JS; Blazar BR; Casson D; Bland-Ward P; Kean LS
    Sci Transl Med; 2017 Sep; 9(408):. PubMed ID: 28931653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual mTORC1/C2 inhibitors: gerosuppressors with potential anti-aging effect.
    Sousa-Victor P; García-Prat L; Muñoz-Cánoves P
    Oncotarget; 2015 Sep; 6(27):23052-4. PubMed ID: 26375366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.